Robert G Gish Consultants

02/13/2026

Join me on March 14-15 in Oceanside, California at the 40th Annual New Treatments in Chronic Liver Disease Conference — a premier meeting focused on the latest advances in hepatology care 🩺

This year’s program highlights cutting-edge updates in:
✔️ PBC & PSC
✔️ Viral hepatitis
✔️ HCC
✔️ Liver transplantation
✔️ Emerging therapeutics and clinical trials

If you’re caring for patients with chronic liver disease, this conference delivers practical, evidence-based insights you can apply immediately in practice

📌 Register here: https://scrippshealthcme.cloud-cme.com/course/courseoverview?P=5&EID=3124

🎉 Discount codes are available!
- MDs use "MD50LIV26"
- APCs use "APP25LIV26"

Hope to see many of you there as we continue advancing liver care together! ✅

02/12/2026

📣Webinar announcement! 🩺 HBV Reactivation

Join me and Kristine Drozd on Thursday, March 5 at 3pm EST for this upcoming AASLD webinar!

Register online now at https://www.aasld.org/events-and-webinars

We will be discussing the most up-to-date guidelines for the HBV reactivation (HBVr) and the indications for HBV prophylaxis for immunosuppressed patients and will offer case presentations

02/05/2026

🌟 Advance Your Clinical Skills with High-Value CME! 🌟

I am excited to invite you to join the “Multidisciplinary Collaboration and Education: Learning to Recognize and Manage the Patient with AATD-LD” - a free CME group hosted by the American Academy of Allergy, Asthma, and Immunology (AAAAI)!

📘 This interactive online continuing medical education activity focuses on improving clinical recognition and management of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (AATD-LD) — a frequently underdiagnosed condition with significant implications for patient outcomes

✔️ Earn 4.75 AMA PRA Category 1 Credits™
✔️ Dive into evidence-based diagnostic strategies, interpretation of testing, and practical management tools
✔️ Participate in live discussions, case reviews, and gain actionable insights for your practice

Whether you’re a clinician, specialist, or allied health provider, this CME program is designed to enhance your knowledge and improve patient care. 🌐

👉 Click here to join the group & get started:
https://aaaai.gathered.com/invite/9wdL9rAejP

Stay on the cutting edge of care-learn, connect, and grow! 💡📈

Join me in an online, private, small-group educational experience where you will learn how to recognize, treat, and appropriately refer patients with AATD-LD. This collaborative, social learning experience offers FREE CME/CE credits!

02/02/2026

📣Hot off the press - A great advance as we are recommending all HBV patients have one anti-HDV total antibody in their charts

January 29, 2026

Diasorin (FTSE MIB: DIA) announced today it has secured U.S. Food and Drug Administration (FDA) De Novo authorization for the first fully automated diagnostic test for hepatitis delta virus (HDV) on the Diasorin LIAISON XL immunoassay system. Designated as a Breakthrough Device by the FDA, the test aids in the diagnosis of HDV in individuals living with acute and chronic hepatitis B virus (HBV). The development of the automated diagnostic assay has been supported by Gilead Sciences.

"Marking a major advancement for patients with hepatitis B, the FDA De Novo authorization of an automated total anti HDV test provides clinicians with a standardized and reliable routine method for detecting HDV co infection and super-infection - a key driver of accelerated progression to cirrhosis and liver failure," said Dr. Robert Gish, Medical Director of the Hepatitis B Foundation. "Broad access to accurate HDV testing will enable earlier identification and more informed clinical management across U.S. practices".

Read the full press release here:
https://us.diasorin.com/en/company/newsroom/press-releases?f%5B0%5D=year%3A2026

02/02/2026

📢 Liver Learning Webinar 🧠🩺Join AASLD Special Interest Group

I encourage colleagues caring for patients with liver disease to check out this timely AASLD Liver Learning webinar on Met-HBV. It offers practical, evidence-based insights that can be directly applied to clinical practice and patient care🎓 Great opportunity to stay current with evolving data and expert perspectives in hepatology.

Join AASLD and be part of the Hepatitis B/Delta Special Interest Group to connect with experts, stay current on evolving science and clinical practice, and help advance care for your patients.

👉 Learn more & get involved: https://www.aasld.org/special-interest-groups/hepatitis-bdelta

🔗 Register for Met-HBV webinar:
https://liverlearning.aasld.org/Public/Catalog/Details.aspx?id=T%2bMPZYfYQWjeYun4rqCIfQ%3d%3d&returnurl=%2fUsers%2fUserOnlineCourse.aspx%3fLearningActivityID%3dT%252bMPZYfYQWjeYun4rqCIfQ%253d%253d

🧬📚

01/30/2026

📄 I’m pleased to share my newly published article in Liver International: http://dx.doi.org/10.1111/liv.70508

🩺 In my clinical practice, I counsel patients with MASH on the importance of weight loss and sustained behavior modification, framing the discussion around the top three leading causes of death: cardiovascular disease, cancer, and liver disease

📉 By addressing obesity and key components of metabolic syndrome, we have a meaningful opportunity to reduce cardiovascular events, cancer risk, and liver-related mortality

🔬 This article highlights emerging evidence supporting lifestyle-based interventions as a cornerstone of MASH management and long-term risk reduction

I hope this work is helpful for clinicians caring for patients with metabolic liver disease

This retrospective observational cohort study was conducted using 100% Medicare fee-for-service claims data (10/01/2015–12/31/2021) to characterise risk of incident extrahepatic cancer in patients wi...

01/28/2026

📣 Join Us for the San Diego Liver Walk! 💛👟

I am excited to again support the San Diego Liver Walk this year— a meaningful community event organized by Liver Coalition of San Diego bringing awareness to liver health and raising funds for local education and support programs! 🌟 Whether you walk, donate, or cheer us on, your participation makes a difference ❤️

🗓 Date: Saturday, March 21
📍 Location: NTC Park, Liberty Station — San Diego, CA
🕗 Schedule:
• 8:00 AM — Registration & Resource Fair opens
• 9:00 AM — Warm-up & Walk begins
• 10:30 AM — Picnic, music & celebration
• 1:00 PM — Festivities conclude

Watch our latest video to learn more:
https://www.youtube.com/watch?v=7yzJzkemQqs

This event is family-friendly, dog-friendly, and FREE to register! 🐾 Bring your friends, family, and even your furry companions for a fun walk while supporting liver health education and services here in our community 💪🌈

👉 Register or donate here: https://runsignup.com/Race/CA/SanDiego/SanDiegoLiverWalk

Let’s walk together toward a healthier future — hope to see you there! 💙💛

01/21/2026

📢 Clinicians: Don’t miss this free AASLD webinar 🎓

Managing patients with chronic hepatitis B and MASLD can be challenging. This timely webinar will review practical approaches to diagnosis, risk stratification, and management at the intersection of metabolic liver disease and HBV

🗓 Thursday, January 29
🕛 12:00–1:00 pm ET

Met-HBV: Diagnosis and Management of MASLD in Patients with Chronic HBV Infection
✔️ Non-invasive assessment
✔️ Metabolic comorbidities
✔️ Integrated care strategies
✔️ Real-world clinical considerations

👉 Register here: https://www.aasld.org/webinar-met-hbv-diagnosis-and-management-masld-patients-chronic-hbv-infection

Moderator: Joseph Lim, MD Speakers: Swathi Krishnan, MD, Jiyoon Park, MD

01/19/2026

Join the Wilson Disease Association (WDA) on January 29 for its virtual Externally Led-Patient Focused Drug Development (EL-PFDD) Meeting where patient and caregiver experiences directly inform drug development.

💬 “This is not just a meeting—it’s a historic opportunity for the Wilson disease community to be heard by those who can drive real change,” — Rhonda Rowland, WDA President

🔹 Highlights
-Selected patient/caregiver conversation starters
-Interactive participation: polling, call-ins, written comments (portal now open)
-Insights compiled in a Voice of the Patient Report for FDA and product developers

🩺 Expert speakers
Dr. Michael Schilsky Yale WD Center of Excellence
Dr. Fred Askari, Michigan Medicine WD Center of Excellence
Dr. Aimee Magnarelli, FDA (CBER)

📌 RSVP here: https://lnkd.in/gby7UYFJ

01/16/2026

📄 New year and another new publication I’m excited to share!

Please read my latest article on metabolic dysfunction–associated steatotic liver disease (MASLD/MASH) and the growing need for focused research and action to address this global health challenge

https://onlinelibrary.wiley.com/doi/10.1111/liv.70508

In my own practice, when counseling patients on weight loss and lifestyle change for MASH, I often emphasize an important motivator: reducing cancer risk. There is a clear association between weight loss and lower cancer risk, which can be a powerful driver for sustained change

Grateful to contribute to this important conversation—and hopeful it helps move the field forward

This retrospective observational cohort study was conducted using 100% Medicare fee-for-service claims data (10/01/2015–12/31/2021) to characterise risk of incident extrahepatic cancer in patients wi...

01/13/2026

💡New article alert! 🩺

Alkaline phosphatase remains a keystone tool in assessing PBC patients' status baseline, and for prognosis and risk of disease progression, as well as treatment response to first and second-line therapy, alongside GGT and liver function tests such as total and direct bilirubin

➡️Read more here:

Alkaline phosphatase (ALP) is a key biomarker in the management of primary biliary cholangitis (PBC). However, evidence of economic benefits of normal ALP is limited. We evaluated the relationship ...

01/12/2026

Want to join me at the Chronic Liver Disease Foundation Liver Connect Conference in February? This is an important meeting bringing together patients, advocates, clinicians, and researchers to advance liver health and innovation 🌍🧬

👉 Complimentary registration is available — use the code GISH100 when you sign up!

This event offers timely education, meaningful discussions, and opportunities to connect with others who are passionate about improving outcomes across liver disease.

Learn more and register here: https://www.liverconnect.org/

I hope to see you there!